Tenderwize
Zurück zur Suche

Open house Nilotinib discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 04, 2027 · 129 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical companies can enter into non-exclusive discount agreements with AOK Bayern for Nilotinib (ATC L01EA03).
  • Exclusion: Nilotinib dispersed in applesauce unless the manufacturer holds patent protection.
Vollständige Zusammenfassung anzeigen

This is an open-house model (not a competitive tender) by AOK Bayern for non-exclusive discount agreements on Nilotinib (ATC L01EA03). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and a signed contract along with an annex listing the medicines. The agreement runs from 01.03.2025 to 28.02.2027, with possible termination with one month's notice. The open-house model is not subject to procurement law; the form is used only due to lack of a dedicated form. No estimated value is provided.

Risiken

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company.
  • Proof of authorization to sign (commercial register extract or power of attorney).

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house Nilotinib discount agreements

Non-exclusive discount agreements for Nilotinib (ATC L01EA03), excluding Nilotinib dispersed in applesauce unless patent-protected. All interested pharmaceutical companies meeting eligibility can join. The contract is standard and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Feb 2025 - Feb 2027

Kategorie

Pharmaceutical products

Frist

Deadline Jan 05, 2027

Vergabedetails

Veröffentlichungsdatum
21 Jan 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
44907-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30